Zim Laboratories Ltd (ZIMLAB) is currently trading at 126.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zim Laboratories is a vertically integrated Indian specialty generics and nutraceuticals company focused on differentiated oral solid dosages, operating three manufacturing facilities and a dedicated R&D centre, and commercializing novel platforms such as Thinoral patented Oral Thin Film (OTF) technology across RoW, EU and Pharmerging markets. The company reports Q1 FY27 revenue of INR 942 million (31.2% YoY), with exports contributing ~84% of total operating income and a high gross margin of 58.1%; EBITDA was INR 34 million (3.7%) and PAT was negative INR 40 million, reflecting planned investments and one‑time remediation costs. EU‑GMP remediation is the single largest strategic hinge: management completed reinspection in May 2026, received a draft inspection report, has CAPA ready to submit upon final report receipt, and expects the regulatory outcome to unlock 8–10 market authorizations and substantial regulated‑market supply opportunities. Innovation and filing momentum is significant: FY26 saw 57 regulatory filings (14 NIP, 29 OTF, 14 finished formulations), Q1 R&D investment was INR 82 million, and the NIP/OTF and oral insulin portfolio contributed ~18% of Q1 revenue — signalling product differentiation emphasis and near‑term commercialization levers.

Over the past 52 weeks, Zim Laboratories Ltd has traded between a low of ₹59.72 and a high of ₹160.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zim Laboratories Ltd has a market capitalization of approximately 679.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zim Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 183.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 679.32 Cr, Zim Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zim Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zim Laboratories Ltd is 183.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting is scheduled for Tuesday, May 19, 2026.